Cholangiocarcinoma and liver transplantation: What we know so far?

doi:10.4291/wjgp.v12.i5.84

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 5

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11218)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

444

WORD

112

HTML

4471

Figures (1-1)

608

Tables (1-5)

845

Sum=6480

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

521

Download

1537

Sum=2058

Publishing Process of This Article

Item

Count

Browse

755

Download

1925

Sum=2680

Sep 22, 2021 (publication date) through Mar 1, 2026

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pathophysiology

ISSN

2150-5330

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Gastrointest Pathophysiol. Sep 22, 2021; 12(5): 84-105
Published online Sep 22, 2021. doi: 10.4291/wjgp.v12.i5.84

Cholangiocarcinoma and liver transplantation: What we know so far?

Ali Reza Safarpour, Hassan Askari, Farshid Ejtehadi, Asaad Azarnezhad, Ehsan Raeis-Abdollahi, Amir Tajbakhsh, Mohammad Foad Abazari, Firoozeh Tarkesh, Alireza Shamsaeefar, Ramin Niknam, Gholam Reza Sivandzadeh, Kamran Bagheri Lankarani, Fardad Ejtehadi

Ali Reza Safarpour, Hassan Askari, Firoozeh Tarkesh, Ramin Niknam, Gholam Reza Sivandzadeh, Fardad Ejtehadi, Department of Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz 7134814336, Iran

Farshid Ejtehadi, The Princess Alexandra Hospital HNS Trust, Harlow, Essex CM20 1QX, United Kingdom

Asaad Azarnezhad, Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj 6617913446, Iran

Ehsan Raeis-Abdollahi, Department of Basic Medical Sciences, Qom Medical Branch, Islamic Azad University, Qom, Iran

Amir Tajbakhsh, Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz 7134814336, Iran

Mohammad Foad Abazari, Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran 1417653761, Iran

Alireza Shamsaeefar, Shiraz Organ Transplant Center, Shiraz University of Medical Sciences, Shiraz 7193711351, Iran

Kamran Bagheri Lankarani, Health Policy Research Centre, Shiraz University of Medical Sciences, Shiraz 7134814336, Iran

Author contributions: Safarpour AR, Azarnezhad A, Abazari MF, Ejtehadi F, Ejtehadi F, Shamsaeefar A, Niknam R, Sivandzadeh GR, and Tarkesh F collected data; Raeis-Abdollahi ER, Askari H, and Tajbakhsh A collected data and partly drafted the first version of the paper; Ejtehadi F, Safarpour AR, Askari H, and Lankarani KB designed, revised, and finalized the manuscript.

Conflict-of-interest statement: The authors declare no conflict of interest.

Corresponding author: Fardad Ejtehadi, MD, Assistant Professor, Department of Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Khalili St, Shiraz 7134814336, Iran. edjtehadif@sums.ac.ir

Received: March 3, 2021
Peer-review started: March 3, 2021
First decision: April 19, 2021
Revised: April 28, 2021
Accepted: August 11, 2021
Article in press: August 11, 2021
Published online: September 22, 2021
Processing time: 196 Days and 9 Hours

Abstract

Cholangiocarcinoma (CCA) is a type of cancer with increasing prevalence around the world that originates from cholangiocytes, the epithelial cells of the bile duct. The tumor begins insidiously and is distinguished by high grade neoplasm, poor outcome, and high risk for recurrence. Liver transplantation has become broadly accepted as a treatment option for CCA. Liver transplantation is expected to play a crucial role as palliative and curative therapy for unresectable hilar CCA and intrahepatic CCA. The purpose of this study was to determine which cases with CCA should be subjected to liver transplantation instead of resection, although reported post-transplant recurrence rate averages approximately 20%. This review also aims to highlight the molecular current frontiers of CCA and directions of liver transplantation for CCA.

Keywords: Cholangiocarcinoma; Liver transplantation; Primary sclerosing cholangitis; Neoadjuvant chemoradiotherapy

Core Tip: Currently, there are many controversial hypotheses concerning liver transplantation in cholangiocarcinoma (CCA) and risk factors and molecular pathogenesis of CCA, with a focus on primary sclerosing cholangitis. Here, we mainly review the current advances in classification and treatment of CCA.